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ABSTRACT 
Objective: The present study was aimed to enhance the solubility of poorly water-soluble drug (BCS Class II) Febuxostat using water-soluble polymers.  
Methods: Pre-formulation studies like drug excipient compatibility studies by Fourier-transform infrared spectroscopyDifferential scanning 
calorimetry and determination of saturation solubility of drug individually in various media like distilled water and pH 7.4 phosphate buffer. Solid 
dispersions of Febuxostat was prepared using Polyethylene glycol (PEG 6000) (fusion method) and Polyvinyl pyrrolidone (PVP K30) (solvent 
evaporation method) in various ratios like 1:1, 1:2, 1:3 and 1:4 separately. The formulated solid dispersions were evaluated for percentage yield, 
drug content and in vitro dissolution studies.  
Results: From the results of pre-formulation studies it was revealed that there was no interaction between drug and excipients and the pure drug was 
poorly soluble in water. The percentage yield of all formulations was in the range of 54-78 %, and drug content was in the range of 43-78 mg. The solid 
dispersion containing polyvinylpyrrolidone K 30 in 1:4 ratio showed the highest amount of drug release at the end of 30 min than other formulations.  
Conclusion: Finally it was concluded that solid dispersion prepared with PVP K-30 in 1:4 ratio by solvent evaporation method was more soluble 
than by fusion method. 
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The solubility/dissolution behavior of a drug is the key factor 
influencing its oral bioavailability, being the rate-limiting step for 
absorption of drugs from the gastrointestinal tract. Consequently 
poor solubility results in low bioavailability increase in the dose, 
large inter-and intra-subject variation and large variations in plasma 
drug concentrations under fed versus fasted conditions [1, 2].  
Dissolution and solubility are two important parameters which alter 
oral bioavailability of any drug; thus efforts should be done to 
improve the solubility and dissolution rate is essential. 
Characteristics of the drugs can be altered by converting them into 
salt forms, size reduction, and by adding surfactants [3]. 
Based on the solubility of the drug and its gastrointestinal 
permeability, they become the fundamental parameters for rate 
controlling and extent of drug absorption inside the body. The 
Biopharmaceutics Classification System correlates the in vitro drug 
dissolution and in vivo bioavailability. 
To determine the bioavailability of fast dissolving drugs with high 
solubility, a simple one point dissolution test and for drugs dissolving 
slowly, a multiple point dissolution test should be performed which 
includes low pH, physiological pH, and surfactants so that the in vitro 
conditions should a mirror as that of the in vivo process [4, 5]. 
Solid dispersion refers to a group of solid products consisting of at 
least two different components, generally a hydrophilic matrix and a 
hydrophobic drug. The matrix can be either crystalline or 
amorphous [6, 7]. 
The present study was aimed to enhance the solubility of poorly 
water-soluble drug (BCS Class II) Febuxostat using water-soluble 
polymers PEG 6000 and PVP K30. 
MATERIALS AND METHODS 
Febuxostat gift sample was obtained from Ranbaxy, Mumbai, 
Polyethylene glycol 6000 from Borenpharm Co., Ltd, Povidone from 
Sigma-Aldrich, Ethanol from Changshu Hongsheng fine chemicals 
Co., Ltd., Potassium dihydrogen phosphate from Merck Specialties 
Private Limited, Sodium hydroxide from Lobal Chemie Laboratory 
Reagents and Fine Chemicals. 
Preparation of PH 7.4 phosphate buffer 
Potassium dihydrogen phosphate, 0.2N 
About 28.2 g of potassium dihydrogen phosphate was dissolved in 
small amount of water and then diluted to 1000 ml with water. 
Sodium hydroxide, 0.2N 
About 8 g of sodium hydroxide was dissolved in small amount of 
water and then diluted to 1000 ml with water. 
pH 7.4 phosphate buffer 
About 50 ml of 0.2N potassium dihydrogen phosphate was taken in a 
200 ml volumetric flask. To this 39.1 ml of 0.2N sodium hydroxide 
solution was added and diluted to 200 ml with water. 
Determination of λMAX for febuxostat in PH 7.4 phosphate 
buffer 
About 100 mg of Febuxostat was accurately weighed into 100 ml 
volumetric flask. Volume is made up to 100 ml using pH 7.4 phosphate 
buffer after dissolving Febuxostat completely. 20 ml was pipetted out 
from the above solution and diluted to 100 ml using pH 7.4 phosphate 
buffer. The solution was diluted suitably and scanned in the range of 
200-400 nm using UV Spectrophotometer with pH 7.4 phosphate 
buffer as blank. From the spectrum obtained, the λmax for Febuxostat 
was found to be 315 nm in pH 7.4 phosphate buffer [8]. 
Standard graph for febuxostat in PH 7.4 phosphate buffer 
About 100 mg of Febuxostat was accurately weighed into 100 ml 
volumetric flask. Volume is made up to 100 ml using pH 7.4 
phosphate buffer after dissolving Febuxostat completely. This is the 
primary stock solution, and from this primary stock solution, 20 ml 
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was withdrawn and made up to 100 ml with pH 7.4 phosphate 
buffer. This is called secondary stock solution. From the above 
solution, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 ml was withdrawn and made 
up to 10 ml with pH 7.4 phosphate buffer separately to produce 2 to 
20 µg/ml concentrations respectively. Using UV spectrophotometer 
the absorbances of these diluted solutions were measured at λmax 
of 315 nm with pH 7.4 phosphate buffer as blank. Standard graph of 
the febuxostat was plotted with concentration (µg/ml) in x-axis and 
absorbance at 315 nm in y-axis is shown in.1. The concentrations 
and its absorbances were subjected to linear regression analysis, 
and the regression equation was found to be   , 
and correlation coefficient (r2) was found to be 0.990 
 
 
Fig. 1: Standard curve of febuxostat in pH 7.4 phosphate buffer 
 
Pre-formulation studies 
Drug-excipient compatibility studies 
FTIR study 
For all the formulations and Febuxostat, the pellets have been 
prepared using potassium bromide for FT-IR study. The pellets were 
subjected to FT-IR instrument ‘Perkin Elmer FTIR spectrometer, 
spectrum 1000 Germany’ for the collection of IR spectra which are 
illustrated in fig. 2 to 4 [9]. 
Differential scanning colorimeter (DSC) studies 
Differential scanning calorimetry was done by using Differential 
scanning calorimeter ‘PerkinElmer’ to obtain the thermograms. Sample 
after weighing accurately were placed in an aluminum pan and another 
empty aluminium pan was used as the reference. The scanning was done 
under nitrogen flow at a scanning rate 10 °C/min in range of 30-450 °C. 
Thermograms were obtained for pure drug, Febuxostat, Polyethylene 
glycol (PEG) 6000 and Polyvinylpyrrolidone (PVP) K 30 alone and also 
for combinations of the pure drug with the polymer in 1:1 ratio 
individually. The results are shown in fig. 5 to 8.  
Determination of saturation solubility 
Using the agitation method, the Solubility study was performed, and 
saturated solution of Febuxostat was prepared using distilled water 
and pH 7.4 phosphate buffer and it was stirred for 24 h. The solution 
filtered through whatmann filter paper 0.45 μm after centrifuging 
for 15 min over 10,000 rpm. The concentration of Febuxostat was 
determined using UV-visible spectrophotometer against respective 
solvent as blank at λmax of 315 nm. The results are shown in table 1. 
 
Table 1: Saturation solubility of febuxostat in various medias 
Name of the media Saturation solubility of drug  (in mg/ml) 
Distilled water 0.84 
pH 7.4 phosphate buffer 1.56 
 
Development of solid dispersion 
By fusion method  
The solid dispersion of Febuxostat and PEG 6000 prepared in four 
different weight ratios (1:1, 1:2, 1:3 and 1:4) and denoted as FF1, 
FF2, FF3 and FF4, respectively. With constant stirring Febuxostat 
was added to molten PEG 6000 and resulting homogenous 
dispersion was allowed to solidify. The solid dispersion thus formed 
was ground in the mortar and sieved to produce uniform particle 
size dispersion. Formulation codes are shown in table 2. 
 
Table 2: Formula for the preparation of solid dispersion of febuxostat with different polymers 






























By solvent evaporation method 
Solid dispersion of Febuxostat and PVP K-30 were prepared in four 
different weight ratios (1:1, 1:2, 1:3 and 1:4) and denoted as FF5, 
FF6, FF7 and FF8, respectively. The required quantity of PVP K-30 
was dissolved in ethanol and to this Febuxostat was added. The 
resulting solution was then homogenized thoroughly and 
evaporated the solvent. Complete removal of solvent was achieved 
by drying the mass obtained in the oven at 40 °C for 24 h.  
The produced. Solid dispersion was then ground, sieved and kept for 
further analysis. Formulation codes are shown in table 2. 
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Characterization of solid dispersion 
Determination of percentage yield 
Percentage yield was calculated for each batches of solid dispersion 
with respect to theoretical yield and practical yield. The results are 
shown in table 3. 
 
Estimation of drug content in solid dispersion 
Sample containing 50 mg of prepared solid dispersion was 
accurately weighed and dissolved in freshly phosphate buffer pH 7.4 
in a 100 ml volumetric flask. The volume was made up to 100 ml 
with phosphate buffer pH 7.4. The absorbance of the resulting 
solution was measured at 315 nm for Febuxostat, against blank 
(phosphate buffer pH 7.4) using UV spectrophotometer. The results 
are shown in table 3. 
In vitro dissolution rate studies on solid dispersions 
The In vitro dissolution for the prepared solid dispersions was 
performed using Labindia Disso 2000 dissolution test apparatus. 
Solid dispersions equivalent to 100 mg of Febuxostat were filled 
in empty hard gelatin capsules were placed in 900 ml of pH 7.4 
phosphate buffer as dissolution medium. The speed was 
maintained at 50 rpm using the paddle for 30 min. The 
temperature of the dissolution medium was maintained constant 
at 37±0.5 °C throughout the study. Samples of about 10 ml were 
pipette out at regular time intervals at 10, 20 and 30 min. The 
sink condition was maintained by replacing with an equal 
volume of fresh dissolution medium. The withdrawn aliquots 
were filtered through whatmann filter paper 0.45 μ, suitably 
diluted and assayed for Febuxostat at 315 nm using UV 
spectrophotometer. The dissolution experiments were 
conducted in triplicate. The results are shown in fig. 9 [10]. 
RESULTS AND DISCUSSION 
Pre-formulation studies 
Drug-excipient compatibility studies (FTIR) 
The FTIR studies were shown in fig. 2 to 4. From the results of pre-
formulation studies, it was revealed that there no chemical 
incompatibility between drug and excipients from FTIR studies. 
 
 
Fig. 2: FTIR for febuxostat 
 
 
Fig. 3: FTIR for povidone 
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Fig. 5: DSC thermogram for febuxostat 
 















































Fig. 6: DSC thermogram for febuxostat with polymer in 1:1 ratio 
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Fig. 8: DSC thermo gram for povidone 
 
Drug-excipient compatibility studies (DSC) 
The DSC thermogram shown in fig. 5 to 8, there was a sharp endotherm 
peak at 87 °C and 275 °C which was shifted to 104 °C and 279 °C when it 
is combined with the polymer at 1:1 ratio. From the results of pre-
formulation studies, it was revealed that there no chemical 
incompatibility between drug and excipients from DSC studies. 
Determination of saturation solubility 
The saturation solubility studies is shown in table no. 1. It is found 
that the solubility of Febuxostat was higher in pH 7.4 phosphate 
buffer than water. So, pH 7.4 phosphate buffer was chosen as 
dissolution media for in vitro dissolution studies. 
 
Characterization of solid dispersion 
 
Table 3: Characterization of solid dispersion of febuxostat 
Formulation code Percentage yield  (% w/w) Drug content (mg) 
FF1 58 43 
FF2 64 48 
FF3 78 45 
FF4 71 51 
FF5 54 64 
FF6 68 59 
FF7 54 62 
FF8 74 78 
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Determination of percentage yield 
The percentage yield for various ratios of different drug and 
polymer were calculated and shown in table 3. The results 
revealed that the percentage yield was high in 1:4 ratio solid 
dispersion prepared by solvent evaporation method than 
compared to the fusion method.  
Estimation of drug content in solid dispersion 
The drug content for various ratios of different drug and 
polymer were calculated and shown in table 3. The results 
revealed that the drug content was high in 1:4 ratio solid 
dispersion prepared by solvent evaporation method than 
compared to the fusion method.  
In vitro dissolution rate studies on solid dispersions 
In vitro dissolution study was carried out with solid dispersions 
prepared by various methods in various ratios are given in fig. 9. 
From the results obtained, the percentage drug released at the 
end of 30 min was found to be high in solid dispersion 
containing PVP K30 (1:4 ratio) than other solid dispersion of 
PVP K30 and PEG 6000 in various ratios which may be due to 
increased entrapment of drug in solvent evaporation method 
than fusion method. 
 
 
Fig. 9: In vitro dissolution profile for solid dispersions of 
febuxostat (Results are expressed as mean±SD, n=3) 
 
CONCLUSION 
Febuxostat is a xanathine oxidase inhibitor indicated in patients 
with gout suffering from hyperuricemia and is used in its chronic 
management has low bioavailability when given orally because it is a 
poorly water-soluble drug with a plasma elimination half-life of 5-8 
h. We conclude that the present study of the formulation 
development for the BCS Class II drug Febuxostat by solvent 
evaporation method was better than Fusion method in the 1:4 ratio 
were increase the solubility and dissolution rate.  
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